Phantom Neuro Highlights Peripheral Neurotech Approach for Scalable Human–Machine Interfaces

According to a recent LinkedIn post from Phantom Neuro, Founder and CEO Connor Glass appeared on Ashlee Vance’s “Core Memory” to discuss the company’s neurotechnology platform, Phantom X. The post highlights that Phantom X is designed to capture electrical signals from the body via an implant under the skin in the limb, rather than through invasive brain-computer interfaces that require brain surgery.

The post suggests that this approach leverages intact upstream neural pathways in individuals with limb loss, enabling intent-driven control of external devices. By focusing on larger, more stable peripheral signals, Phantom Neuro appears to be positioning its technology as a potentially more scalable human–machine interface across medical, neurotech, and defense-related applications.

For investors, the emphasis on scalability and reduced surgical complexity could imply a broader addressable market and potentially lower adoption barriers relative to invasive BCI solutions. If Phantom X proves clinically effective and commercially viable, Phantom Neuro may gain a differentiated position within the neurotechnology and medtech landscape, with optionality in prosthetics, rehabilitation, and defense innovation use cases.

The visibility generated by the Core Memory appearance may also help the company attract strategic partners, research collaborations, or non-dilutive funding in defense and healthcare sectors. However, the post does not provide data on regulatory timelines, clinical outcomes, or revenue prospects, leaving key commercialization and reimbursement risks for investors to monitor through future disclosures and industry developments.